Patrizia Murer

Title: Innovations in Immunotherapy: The Contributions of Patrizia Murer

Introduction

Patrizia Murer is a notable inventor based in Basel, Switzerland. She has made significant contributions to the field of immunotherapy, particularly through her innovative work on immune-stimulating IL-2 fusion proteins. Her research focuses on enhancing the immune response against cancer, showcasing her dedication to advancing medical science.

Latest Patents

Patrizia Murer holds a patent for immune-stimulating IL-2 fusion proteins. This invention relates to the development of immune-stimulating IL-fusion proteins that comprise antibodies joined to human interleukin-(hIL-). More specifically, it involves humanized monoclonal antibodies or fragments thereof that are joined to hIL or variants, which display a unique capability of preferentially stimulating cytotoxic T cells and NK cells compared to Treg cells. The patent also covers in vitro and in vivo therapeutic applications of these IL-fusion proteins, particularly as an immunotherapy in the treatment of cancer.

Career Highlights

Patrizia Murer is currently associated with Anaveon AG, where she continues her groundbreaking work in immunotherapy. Her research has the potential to transform cancer treatment and improve patient outcomes through innovative therapeutic strategies.

Collaborations

Patrizia has collaborated with esteemed colleagues such as Andreas Katopodis and Christoph Huber. These collaborations have further enriched her research and contributed to the advancement of immunotherapy.

Conclusion

Patrizia Murer's contributions to the field of immunotherapy through her patent on IL-2 fusion proteins exemplify her commitment to improving cancer treatment. Her work not only highlights her innovative spirit but also underscores the importance of collaboration in scientific research.